Johnson and Johnson asked to cut down price of new TB drug

Medicines Sans Frontiers (MSF) has called upon US drug maker c (J&J) to cut down the price of its new tuberculosis drug Bedaquiline, as the high price of the drug is depriving patients of best possible treatment, the humanitarian group said on Tuesday.

MSF said that its research shows that the Drug Resistant TB treatment regimes, containing the two new drugs of Bedaquiline and Delamanid represent a significant price increase over older, no-longer-recommended treatment regimens.

The estimated price of longer individualized treatment regimens could now reach more than US$2,000 for people who need at least 18 months of bedaquiline, a 50% price increase over previous standard treatment, MSF said- while those who need both bedaquiline and delamanid for as long as 20 months, the price increase could reach 500%, with a treatment regimen priced at around $9,000.

Though J&J has announced a price reduction for bedaquiline in some countries, where the company has offered to sell the drug at $400 for six months of treatment. But the aid organization said this price is still too high.

“Our analysis clearly shows that the high price of the two newer TB drugs makes today’s best-possible treatment much more expensive than previous treatment regimens,” said Sharonann Lynch, HIV & TB advisor for MSF’s Access Campaign.

Bedaquiline is the first antibiotic against drug resistant TB to have come into the market in 40 years, in August this year the World Health Organization recommended the use of the drug as part of the core treatment against DR-TB, instead of the injection regimen which is currently under use.

J&J received substantial taxpayer money from the US and other governments for the development of bedaquiline, and therefore has a clear responsibility to make sure the public gets a return on this investment by making the drug affordable for everyone who needs it.

To ensure the drug is accessible to all, MSF called on J&J to issue a non-exclusive license to the Medicines Patent Pool to allow for price-lowering competition among generic producers.

MSF in its public statement said that since J&J received substantial taxpayer money from the US and other governments for the development of Bedaquiline, has a clear responsibility to make sure the public gets a return on this investment by making the drug affordable for everyone who needs it.

  • Related Posts

    • Pharma
    • March 27, 2024
    • 99 views
    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Haryana has blacklisted Maiden Pharmaceuticals Ltd, based at Sonepat, for three years, thereby debarring the firm from participating in state tenders. All rate contracts issued to the firm have also…

    • Pharma
    • March 27, 2024
    • 67 views
    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    New Delhi: The Drugs Consultative Committee (DCC), the advisory committee formed by the Central government to advise the Central and state governments on matters that require uniform implementation of drug laws…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Lee Health develops natural capsule for effective Heart care

    Lee Health develops natural capsule for effective Heart care

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down